dr. chu on the role of pembrolizumab in dmmr/msi-h mcrc
Published 3 years ago • 452 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
9:02
pembrolizumab in msi-h crc tumors
-
5:20
pembrolizumab improves on chemo in msi-h/dmmr mcrc
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
1:04
dr. halfdanarson on the keynote-177 trial in msi-h/dmmr mcrc
-
1:28
dr. bekaii-saab on the response rate of pembrolizumab in msi-h crc
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
5:41
role of immunotherapy in microsatellite-stable r/r mcrc
-
8:34
relapsed/refractory mcrc: immunotherapy in msi-high tumors
-
1:08
dr. weinberg on the role of cetuximab in metastatic crc
-
1:28
dr. overman on distinctions between regorafenib and tas-102 in crc
-
3:04
treatment goals in refractory mcrc
-
1:14
current and future trends in immunotherapy for msi-h colorectal cancer
-
1:42
dr. overman on the impact of nivolumab in mcrc
-
1:53
the role of sidedness in colorectal cancer
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:08
first-line durvalumab monalizumab in microsatellite-stable crc
-
9:02
tumor profiling in patients with mcrc
-
0:54
dr. comperat on the treatment strategy for neuroendocrine tumors
-
0:54
dr. diaz on response rates with pembrolizumab for crc